Analysts Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $34.00

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have been given a consensus recommendation of “Strong Buy” by the six research firms that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $34.00.

CPRX has been the topic of several research reports. Citigroup boosted their target price on Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. Zacks Research raised Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Weiss Ratings restated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Monday, December 29th. Finally, Truist Financial raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock opened at $23.40 on Friday. The firm has a market cap of $2.86 billion, a price-to-earnings ratio of 13.85, a P/E/G ratio of 0.68 and a beta of 0.75. The firm’s 50-day simple moving average is $24.01 and its two-hundred day simple moving average is $22.72. Catalyst Pharmaceuticals has a 52 week low of $19.05 and a 52 week high of $26.58.

Institutional Trading of Catalyst Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Rothschild Investment LLC boosted its holdings in Catalyst Pharmaceuticals by 1,085.7% in the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 1,520 shares during the period. Advisory Services Network LLC bought a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at $39,000. Quarry LP purchased a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth $40,000. Clearstead Advisors LLC lifted its position in shares of Catalyst Pharmaceuticals by 192.9% during the fourth quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 1,167 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 55.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 630 shares during the period. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).